Abbott Laboratoriesvs.Quest Diagnostics
ABT vs DGX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 7.4× larger than Quest Diagnostics by market cap; Quest Diagnostics trades at the lower P/E (24.6 vs 35.5); year to date, Quest Diagnostics leads (+40.5% vs −6.9%).
Supply-chain link: Abbott Laboratories supplies Quest Diagnostics.
Side by side
| ABT | DGX | |
|---|---|---|
| Market cap | $193B | $26.1B |
| Price | $116.13 | $244.51 |
| Today | −0.5% | +0.3% |
| Return YTD | −6.9% | +40.5% |
| Return 1Y | −12.0% | +35.3% |
| P/E | 35.5 | 24.6 |
| P/S | 4.1 | 2.3 |
| P/B | 3.8 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →Quest DiagnosticsDGX
A nationwide lab network that does routine testing at volume, with more advanced diagnostics and health data work on top.
Full DGX profile →More ABT & DGX comparisons
Other head-to-heads in the Diagnostics segment.